This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 1 pp 80—105
Ubenimex induces autophagy inhibition and EMT suppression to overcome cisplatin resistance in GC cells by perturbing the CD13/EMP3/PI3K/AKT/NF-κB axis
Figure 1. High expression of CD 13 is a risk stratification strategy for GC patients with CDDP treatment. (A) CD13 expression in serial sections from GC patients with CDDP-based chemotherapy was determined by immunohistochemical staining. Data are shown as the representative images (upper panels) and the staining score of CD13 with the means±SD (bottom panel) from three independent experiments. **P<0.01. (B) Comparison of CD13 expression between CDDP-sensitive and CDDP-resistant GC patients was conducted by Western blot assay. Data are displayed as the representatives (upper panels), and relative expression with means±SD (bottom panel) from three independent experiments.** P< 0.01. “S” and “R” represented the CDDP-sensitive and CDDP-resistant group, respectively. (C) The overall survival curves of GC patients based on the CD13 expression were generated using the Kaplan-Meier method. *P=0.018 was obtained using a log-rank test, and was considered to be statistically significant.